Tag:

Sanofi

Latest Headlines

Latest Headlines

Sanofi's Merial revives heartworm treatment

Spring ended with approval for a chewable treating ticks and fleas in May, followed by another edible drug in June for canine osteoarthritis. Now the market for dog meds is getting even bigger as Sanofi's Merial has just relaunched its heartworm tablet.

Reuters: Sanofi in $8.5B sell-off talks with Mylan, Abbott, private equity

We know plenty of Big Pharma companies are hawking portfolios of old products. What we don't know is who might buy them. One answer came earlier this week, when Mylan said it would acquire an ex-U.S. portfolio of Abbott Laboratories meds in a $5.3 billion stock swap. Now, it might be Sanofi's turn--and Mylan and Abbott are part of that chatter, too.

Sanofi and others hit hard by India's price caps on heart and diabetes drugs

The pharma sector in India is reeling after the National Pharmaceutical Pricing Authority said it's capping prices on about 100 drugs to treat diabetes and heart disease. And the company that could suffer most isn't India-based.

Solid PhIII brings Sanofi closer to blockbuster dengue sales

A new batch of results from a large-scale Phase III trial of Sanofi's dengue candidate holds mostly good news for French drugmaker, which is on track to produce the world's first vaccine for the deadly disease. But while the candidate showed itself to be by-and-large safe and effective, it once again faltered against serotype 2, the same variant that tripped it up in an earlier trial.

Sanofi's $1.5B dengue vaccine shows Phase III promise, but questions linger

Capping a 20-year effort to develop the world's first dengue fever vaccine, Sanofi has come through with positive results from a sweeping Phase III trial, but its candidate is not quite a panacea for the often deadly disease.

Regeneron, Sanofi herald a blockbuster contender with groundbreaking study

If you want to understand why Regeneron R&D chief George Yancopolous gets a king's ransom in annual compensation, you need look no further than the Phase IIb data that has just been posted on dupilumab for severe eczema.

Which big brands will still be bringing in the big bucks in 2020?

Best-selling drugs did well for themselves in 2013, churning out more than $76 billion in sales. But big-name brands could stand the test of time and help the top 10 rake in more than $80 billion in 2020, according to a new report.

Sanofi hits Lilly with more Lantus infringement charges

Sanofi has already slapped Eli Lilly with one patent infringement lawsuit over its Lantus copy, effectively keeping the competitor off the market until at least mid-2016. But now, it's filed another, wider suit.

Sanofi ups the legal ante to block Lilly's Lantus biosimilar

Sanofi has filed another lawsuit against Eli Lilly in hopes of beating back a biosimilar challenge for its top-selling insulin product, claiming its rival's in-development knockoff infringes its intellectual property.

Sanofi Pasteur taps CureVac for its RNA vaccine tech

Germany's CureVac will implement its RNA stabilizing RNActive technology in its new collaboration with French firm Sanofi Pasteur to develop a messenger RNA-based vaccine targeting an undisclosed pathogen.